Cite
MLA Citation
Ruben A Mesa et al.. “Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial.” Lancet, vol. 4, no. 5, 2017, pp. e225–e236. http://access.bl.uk/ark:/81055/vdc_100045920700.0x000009